(1 - 6 von 19
)
1st dcSSc Patients Dosed, Enrollment Open in Phase 2a ...Scleroderma News
sclerodermanews.com
— ... was limited due to local regulations around the current pandemic,” Joachim Schupp, EHP's chief medical officer, said in a press release.
Imprimis Pharma acquires IP for bleeding & clotting disorder ...
www.pharmabiz.com
— Imprimis chief medical officer Dr Joachim Schupp explained, "Control of bleeding and infection is an integral part of the wound healing ... › News...
Imprimis Pharma gets IRB approval to begin phase III trial ...Pharmabiz.com
www.pharmabiz.com
— ... central ethics committee, Schulman Associates Institutional Review Board, Inc.," said Imprimis chief medical officer Dr Joachim Schupp.
sortiert nach Relevanz / Datum